Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci [0.03%]
Genome-wide association研究鉴定的疾病风险位点对多种硬化症患者进行醋酸格拉替雷治疗的药物基因组学影响
Olga Kulakova,Vitalina Bashinskaya,Ivan Kiselev et al.
Olga Kulakova et al.
Aim: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. ...
SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma [0.03%]
中国非霍奇金淋巴瘤患者SLCO1B1rs4149056基因多态性预测甲氨蝶呤毒性的研究
Lin Yang,Hui Wu,Teun van Gelder et al.
Lin Yang et al.
Aim: To investigate the impact of polymorphisms in the FPGS, GGH and SLCO1B1 genes on high dose methotrexate (HD-MTX) related toxicity in Chinese patients with non-Hodgkin lymphoma (NHL). ...
Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? [0.03%]
基于基因型的他克莫司剂量指南：是否包含CYP3A4*22？
Laure Elens,Vincent Haufroid
Laure Elens
Aim: To test the relevance of revisiting the genotype classification based on CYP3A5*3 solely by incorporating CYP3A4*22 information. Methods: ...
Distinctiveness of the Roma population within CYP2B6 worldwide variation [0.03%]
罗马人群体在CYP2B6全球变异中的独特性
Željka Tomas,Antonija Kuhanec,Tatjana Škarić-Jurić et al.
Željka Tomas et al.
Aim: To determine variation of CYP2B6 gene within the genetically specific Croatian Roma (Gypsy) population originating from India and to examine it in the worldwide perspective. ...
Rethinking ovarian cancer genomics: where genome-wide association studies stand? [0.03%]
卵巢癌基因组学的再思考：全基因组关联研究进展如何？
Ricardo Pinto,Joana Assis,Augusto Nogueira et al.
Ricardo Pinto et al.
Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease suscep...
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review [0.03%]
药理基因组学对健康差异影响的评估：系统文献回顾
Antony Martin,Jennifer Downing,Michelle Maden et al.
Antony Martin et al.
This review assessed evidence of disparities in benefits of pharmacogenomics related to 'model performance' in subgroups of patients and studies which reported impact on health inequalities. 'Model performance' refers to the ability of algo...
Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol [0.03%]
CYP2D6和ADRB1基因多态性对美托洛尔术后患者心率的影响研究
Xiaofeng Gao,Huan Wang,Hui Chen
Xiaofeng Gao
Aim: To explore the effect of CYP2D6*10 (100C > T) and ADRB1 1165 G > C polymorphisms on heart rate of post-PCI (percutaneous coronary intervention) patients treated with metoprolol succinate sustained-release tablets. ...
OCT1 pharmacogenetics in pain management: is a clinical application within reach? [0.03%]
疼痛管理中关于OCT1的药物基因组学：是否可以将其应用于临床？
Mladen V Tzvetkov
Mladen V Tzvetkov
Beside drug metabolizing enzymes alsogenetically variable membrane transporters may substantially contribute to the interindividual variability in pharmacokinetics and efficacy of opioids and other analgesics. The organic cation transporter...
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients [0.03%]
基于药物基因组学的泰国艾滋病感染者的替诺福韦药代动力学群体分析
Kanokrat Rungtivasuwan,Anchalee Avihingsanon,Narukjaporn Thammajaruk et al.
Kanokrat Rungtivasuwan et al.
Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: ...
Louise Ladebo,Anne Estrup Olesen
Louise Ladebo